Evidence map›Paper›PMID 35899207›Full record

ArticleFrontiers in medicine2022

Petra Bořilová Linhartová, Ondřej Zendulka, Jaroslav Janošek, Natálie Mlčůchová, Michaela Cvanová, Zdeněk Daněk, Radek Kroupa, Ladislava Bartošová, Břetislav Lipový

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Petra Bořilová LinhartováRECETOX, Faculty of Science, Masaryk University, Brno, Czechia.
Ondřej ZendulkaDepartment of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czechia.
Jaroslav JanošekFaculty of Medicine, Center for Health Research, University of Ostrava, Ostrava, Czechia.
Natálie MlčůchováRECETOX, Faculty of Science, Masaryk University, Brno, Czechia.
Michaela CvanováFaculty of Medicine, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czechia.
Zdeněk DaněkRECETOX, Faculty of Science, Masaryk University, Brno, Czechia.
Radek KroupaDepartment of Internal Medicine and Gastroenterology, Faculty of Medicine, Institution Shared With University Hospital Brno, Masaryk University, Brno, Czechia.
Ladislava BartošováDepartment of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czechia.
Břetislav LipovýDepartment of Burns and Plastic Surgery, Faculty of Medicine, Institution Shared With University Hospital BrnoMasaryk University, Brno, Czechia.
Masaryk University · CZUniversity Hospital Brno · CZUniversity of Ostrava · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To this date, there are no recommendations for personalized stress ulcer prophylaxis (SUP) in critical care that would take the patient's individual genetic predispositions into account. Of drugs used for this purpose, proton pump inhibitors (PPIs) are the first-choice drugs in intensive care unit patients. The degradation of proton pump inhibitors is mediated by cytochrome P450 (CYP) enzymes; in particular, CYP2C19 and, to a lesser extent, CYP3A4 are involved. Expression and metabolic activity of, namely in, CYP2C19 is significantly affected by single nucleotide polymorphisms, the drug metabolization rate varies greatly from ultrarapid to poor and likely influences the optimal dosage. As these CYP2C19 predictive phenotypes via

Indexed as

critical caregene polymorphismpersonalized therapypharmacogeneticspoor metabolizerproton pump inhibitorsstress ulcer prophylaxisultra-rapid metabolizer

Identifiers

PMID35899207
PMCPMC9309431
OpenAlexW4285012281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.